Applied DNA Sciences received a notification from Nasdaq on July 12, 2024, indicating non-compliance with the minimum bid price requirement of $1.00 per share, following 30 consecutive business days of trading below this threshold from May 28 to July 11, 2024. The company has until January 8, 2025, to regain compliance by maintaining a closing bid price of at least $1.00 for a minimum of 10 consecutive business days.The company may be eligible for an additional 180-day compliance period until July 7, 2025, if it meets other Nasdaq Capital Market listing requirements. To address this issue and comply with its Series Warrants provisions, Applied DNA Sciences intends to implement a reverse stock split unless it naturally regains compliance within the given timeframe.The notification does not immediately affect the company's Nasdaq Capital Market listing. However, failure to regain compliance could result in delisting, subject to the company's right to appeal such a determination.

Applied DNA Sciences received a notification from Nasdaq on July 12, 2024, indicating non-compliance with the minimum bid price requirement of $1.00 per share, following 30 consecutive business days of trading below this threshold from May 28 to July 11, 2024. The company has until January 8, 2025, to regain compliance by maintaining a closing bid price of at least $1.00 for a minimum of 10 consecutive business days.The company may be eligible for an additional 180-day compliance period until July 7, 2025, if it meets other Nasdaq Capital Market listing requirements. To address this issue and comply with its Series Warrants provisions, Applied DNA Sciences intends to implement a reverse stock split unless it naturally regains compliance within the given timeframe.The notification does not immediately affect the company's Nasdaq Capital Market listing. However, failure to regain compliance could result in delisting, subject to the company's right to appeal such a determination.